We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA)

This study is currently recruiting participants.
Verified September 2017 by Novartis ( Novartis Pharmaceuticals )
Sponsor:
ClinicalTrials.gov Identifier:
NCT02435849
First Posted: May 6, 2015
Last Update Posted: September 29, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
April 16, 2015
May 6, 2015
September 29, 2017
April 8, 2015
December 15, 2017   (Final data collection date for primary outcome measure)
Overall remission rate (ORR) = CR + CRi [ Time Frame: After all manufactured pts have received CTL019 infuson and completed 3 months from study day 1 infusion or discontinued earlier ]
Efficacy of CTL019 therapy as measured by overall remission rate during the 3 months after CTL019 administration, which includes CR and CR with incomplete blood count recovery (CRi) as determined by IRC assessment.
Overall remission rate (ORR) [ Time Frame: After 50 pts completed at least 6 months follow up ]
Efficacy of CTL019 therapy - ORR includes Complete Remission (CR) and CR with incomplete blood count recovery (CRi) as determined by independent review committee (IRC) assessment.
Complete list of historical versions of study NCT02435849 on ClinicalTrials.gov Archive Site
  • Percentage of patients who achieve best overall response (BOR) or CR or CRi with an MRD negative bone marrow by central analysis using qPCR [ Time Frame: 60 months ]
  • Percentage of patients who achieve CR or CRi at month 6 without SCT between CTL019 infusion and Month 6 response assessment. [ Time Frame: 6 months ]
  • Duration of remission (DOR) [ Time Frame: 60 months ]
  • Percentage of patients who achieve CR or CRi with minimal residual disease negative bone marrow [ Time Frame: 60 months ]
  • Relapse-free survival [ Time Frame: 60 months ]
  • Event-free survival [ Time Frame: 60 months ]
  • Overall survival [ Time Frame: 60 months ]
  • Response at Day 28 +/- 4 days [ Time Frame: 60 months ]
  • Impact of baseline tumor burden on response [ Time Frame: 60 months ]
  • Percentage of patient who achieve CR or CRi and then proceed to SCT while in remission before Month 6 response assessment [ Time Frame: 60 months ]
  • Quality of response using MRD disease assessments before treatment at day 28 +/-4 days after treatment using central assessments by qPCR and before SCT by local assessment (flow or PCR) [ Time Frame: 60 months ]
  • Safety of CTL019 therapy [ Time Frame: 60 months ]
  • Characterize in vivo cellular PK profile of CTL019 cells in target tissues [ Time Frame: 60 months ]
  • Prevalence and incidence of immunogenicity to CTL019 [ Time Frame: 60 months ]
  • Effects of CTL019 therapy on Patient Reported Outcomes [ Time Frame: 60 months ]
  • Derivation of a score to predict cytokine release syndrome [ Time Frame: 60 months ]
  • Describe the profile of soluable immune factors that may be key to cytokine release syndrome [ Time Frame: 60 months ]
  • Describe levels of B and T cells (blood and bone marrow) prior to and following CTL019 infusion for safety monitoring [ Time Frame: 60 months ]
  • Percentage of patients who achieve CR or CRi at Month 6 without SCT between CTL019 infusion and Month 6 response assessment [ Time Frame: 60 months ]
  • Percentage of patients who achieve CR or CRi and proceed to SCT while in remission before Month 6 response assessment [ Time Frame: 60 months ]
  • Duration of remission (DOR) [ Time Frame: 60 months ]
  • Percentage of patients who achieve CR or CRi with minimal residual disease negative bone marrow [ Time Frame: 60 months ]
  • Relapse-free survival [ Time Frame: 60 months ]
  • Event-free survival [ Time Frame: 60 months ]
  • Overall survival [ Time Frame: 60 months ]
  • In vivo cellular PK profile (levels, persistence, trafficking) of CTL019 cells [ Time Frame: 60 months ]
  • Prevalence/incidence of immunogenicity to CTL019 [ Time Frame: 60 months ]
Not Provided
Not Provided
 
Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of CTL019 in pediatric patients with r/r B-cell ALL.
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of CTL019 in pediatric patients with r/r B-cell ALL. The study will have the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment and Primary Follow-up, Secondary Follow-up (if applicable) and Survival Follow-up. The total duration of the study is 5 years from CTL019 cell infusion.
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Lymphoblastic Leukemia
  • Acute
  • Childhood
Biological: Single dose of CTL019
2 to 5 x 10(6) autologous CTL019 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
Experimental: Single dose of CTL019
2 to 5 x 10(6) autologous CTL019 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
Intervention: Biological: Single dose of CTL019
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
March 3, 2022
December 15, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Relapsed or refractory pediatric B-cell ALL.

    1. 2nd or greater Bone Marrow (BM) relapse OR.
    2. Any BM relapse after allogeneic stem cell transplantation (SCT) and must be ≥ 6 months from SCT at the time of CTL019 infusion OR.
    3. Primary refractory as defined by not achieving a CR after 2 cycles of a standard chemotherapy regimen or chemorefractory as defined by not achieving a CR after 1 cycle of standard chemotherapy for relapsed leukemia OR.
    4. Patients with Philadelphia chromosome positive (Ph+) ALL are eligible if they are intolerant to or have failed 2 lines of tyrosine kinase inhibitor therapy (TKI), or if TKI therapy is contraindicated OR.
    5. Ineligible for allogeneic SCT.
  • For relapsed patients, documentation of CD19 tumor expression demonstrated in bone marrow or peripheral blood by flow cytometry within 3 months of study entry.
  • Adequate organ function defined as:

    1. Renal function defined as:

      A serum creatinine based on age/gender as follows:

      Maximum Serum Creatinine (mg/dL). Age Male Female

      1 to < 2 years 0.6 0.6 2 to < 6 years 0.8 0.8 6 to < 10 years 1.0 1.0 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4

      ≥ 16 years 1.7 1.4.

    2. Alanine Aminotransferase (ALT) ≤ 5 times the upper limit of normal (ULN) for age.
    3. Bilirubin < 2.0 mg/dL.
    4. Must have a minimum level of pulmonary reserve as ≤ Grade 1 dyspnea and pulse oxygenation > 91% on room air.
    5. Left Ventricular Shortening Fraction (LVSF) ≥ 28% confirmed by echocardiogram (ECHO), or Left Ventricular Ejection Fraction (LVEF) ≥ 45% confirmed by echocardiogram or Multiple Uptake Gated Acquisition (MUGA).
  • Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening.
  • Life expectancy > 12 weeks.
  • Age 3 at the time of screening to age 21 at the time of initial diagnosis
  • Karnofsky (age ≥ 16 years) or Lansky (age < 16 years) performance status ≥ 50 at screening.
  • Must have an apheresis product of non-mobilized cells received and accepted by the manufacturing site.

Exclusion Criteria:

  • Isolated extra-medullary disease relapse
  • Patients with concomitant genetic syndrome: such as patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Patients with Down Syndrome will not be excluded.
  • Patients with Burkitt's lymphoma/leukemia (i.e. patients with mature B-cell ALL, leukemia with B-cell [sIg positive and kappa or lambda restricted positivity] ALL, with FAB L3 morphology and /or a MYC translocation)
  • Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative intent and with no evidence of active disease
  • Treatment with any prior gene therapy product
  • Has had treatment with any prior anti-CD19/anti-CD3 therapy, or any other anti-CD19 therapy
  • Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening
  • Human Immunodeficiency Virus (HIV) positive test within 8 weeks of screening
  • Presence of grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD).
  • Active CNS involvement by malignancy, defined by CNS-3 per NCCN guidelines.
  • Patient has an investigational medicinal product within the last 30 days prior to screening.
  • Pregnant or nursing women.
  • Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) and all male participants, unless they are using highly effective methods of contraception for a period of 1 year after the CTL019 infusion.
  • The following medications are excluded:

    1. Steroids: Therapeutic doses of steroids must be stopped > 72 hours prior to CTL019 infusion. However, the following physiological replacement doses of steroids are allowed:

      < 12 mg/m2/day hydrocortisone or equivalent

    2. Allogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed > 6 weeks prior to CTL019 infusion
    3. GVHD therapies: Any drug used for GVHD must be stopped > 4 weeks prior to CTL019 infusion (e.g. calcineurin inhibitors, methotrexate or other chemotherapy drugs, mycophenolyate, rapamycin, thalidomide, or immunosuppressive antibodies such as anti-CD20 (rituximab), anti-TNF, anti-IL6 or anti-IL6R)
    4. Chemotherapy:

      The following drugs must be stopped > 1 week prior to CTL019 infusion and should not be administered concomitantly or following lymphodepleting chemotherapy: hydroxyurea, vincristine, 6-mercaptopurine, 6-thioguanine, methotrexate < 25 mg/m2, cytosine arabinoside < 100 mg/m2/day, asparaginase (non-pegylated)

      The following drugs must be stopped >2 weeks prior to CTL019 infusion:

      salvage chemotherapy (e.g. clofarabine, cytosine arabinoside > 100 mg/m2, anthracyclines, cyclophosphamide), excluding the required lymphodepleting chemotherapy drugs Pegylated-asparaginase must be stopped > 4 weeks prior to CTL019 infusion

    5. CNS disease prophylaxis:

      CNS prophylaxis treatment must be stopped > 1 week prior to CTL019 infusion (e.g. intrathecal methotrexate)

  • Anti T-cell therapy: Administration of any T cell or toxic agent is strongly discouraged since residual lytic levels may destroy the infused CTL019 cell or prevent their in vivo expansion.

Other protocol-defined inclusion/exclusion may apply.

Sexes Eligible for Study: All
3 Years to 21 Years   (Child, Adult)
No
Contact: Novartis Pharmaceuticals 1-888-669-6682 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals +41613241111
Australia,   Austria,   Belgium,   Canada,   France,   Germany,   Italy,   Japan,   Norway,   Spain,   United States
 
 
NCT02435849
CCTL019B2202
2013-003205-25 ( EudraCT Number )
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP